Cutaneous lupus erythematosus induced by infliximab in patient with croh n’s disease. A case report

• Autores: Lucía Cid Conde, Dosinda Silveira Cancela, María Perfecta Fernández González
• Localización: European journal of clinical pharmacy: atención farmacéutica, ISSN 2385-409X, Vol. 18, Nº. 5, 2016, págs. 10-10
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Introduction: Drug-Induced Lupus (DIL) or lupus-like syndrome is a rare clinical syndrome that appears months or years after exposure to the drug; the development depends on the accumulated dose and being characteristic the temporal association between ingestion of the drug and the appearance of clinical symptoms and autoantibody; as well as remission of symptoms and decrease in antibody titers following the withdrawal of the same. Infliximab is a chimeric monoclonal antibody indicated for the treatment of severe forms of Crohn’s disease that do not respond to corticosteroids and/or immunosuppressants. We report the case of a patient with Crohn’s disease who presented lupus-like syndrome associated with treatment with infliximab (Remicade®); with a range of occurrence of 3-16 months, serological criteria ANA and non-serological criteria malar rash. We proceeded to final withdrawal of the drug after re-exposure and appearance of new lesions. She was continued only with azathioprine. The patient progressed favourably with resolution of skin lesions and decreasing doses of oral corticosteroids as well as the occasional application of topical corticosteroids.

    Conclusion: The appearance of DIL is an infrequent side effect during treatment with anti-TNF, with an incidence of 0.19 to 0.22% for infliximab, but its administration is not without risk and patients should be closely assessed